Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Apotex Launches Apparent First Abraxane Generic – With Little Fanfare

Teva Was Cleared To Launch From 31 March Under Settlement Agreement

Executive Summary

Apotex has confirmed launch of a generic version of Bristol Myers Squibb’s Abraxane, with details thin on the ground.

You may also be interested in...



Cipla Stays Upbeat On Advair Generic With ‘Superior’ Cost Position, Derisks Abraxane

Generic Revlimid and lanreotide propel Cipla’s US business to a high in the fiscal second quarter, with products like leuprolide depot set for debut ‘any time now’. Management signals cost edge for generic Advair as it awaits further word following a FDA establishment inspection report at its Indian site, while a Plan B is being initiated for generic Abraxane.

Cipla Stays Upbeat On Advair Generic With ‘Superior’ Cost Position, Derisks Abraxane

Generic Revlimid, lanreotide propel Cipla’s US business to a high in the fiscal second quarter, with products like leuprolide depot set for debut ‘any time now’. Management signals cost edge for generic Advair as it awaits further word following a FDA establishment inspection report at its Indian site, while a Plan B is being initiated for generic Abraxane.

OTC Private Label, Rx Generics Firm Apotex To Be Acquired By Private Investment Group

SK Capital announced agreement to acquire Apotex, saying it will invest to “support Apotex’s next phase of growth and continued innovation for patient affordability."

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel